Hims & Hers Health, Inc. (HIMS) company profile
Close on Nov 17, 2026Market cap $4.09BP/E –Yield –
About Hims & Hers Health
Services-Offices & Clinics of Doctors of Medicine, SIC 8011
Hims & Hers Health, Inc. operates a digital consumer healthcare platform that connects patients with licensed healthcare professionals and fulfillment services. The company provides personalized access to prescription medications, compounded treatments, and over-the-counter wellness products focusing on areas such as sexual health, hair loss, dermatology, mental health, and weight management. Additionally, it offers comprehensive laboratory testing and health assessment services directly through its websites and mobile applications, serving consumers primarily on a recurring subscription model.
The company operates across the United States, Canada, the United Kingdom, and parts of the European Union, including Germany, France, Spain, and the Republic of Ireland. Fulfillment and manufacturing operations include two domestic pharmacies, two facilities licensed in the United Kingdom, an outsourcing facility, a peptide facility, and a laboratory center. The provided text details operations across these international regions without stating a specific headquarters location.
Summary of the business section of Hims & Hers Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Hims & Hers Health, Inc.
- Founded
- 2017
- Headquarters
- San Francisco, CA
- Address
- 2269 Chestnut St, #523 94123
- Phone
- (415) 851-0195
- Website
- www.forhims.com
- Employees
- 1,046, Dec 31, 2025
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, CA
Stock & identifiers
- Ticker
- HIMS
- Former tickers
- OACU until Mar 22, 2021; OAC until Aug 13, 2020
- Exchange
- NYSE
- IPO date
- Jul 19, 2019
- Shares outstanding
- 233M, Aug 7, 2026
- Public float
- $10.10B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1773751
- CUSIP
- 433000106
- ISIN
- US4330001060
- FIGI
- BBG00Q53VYM7
- Share class FIGI
- BBG00Q5LQWK9
- LEI
- 254900V041EIVTSB6D58
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Deborah M. Autor | Chief Policy Officer, Director | 72,789 |
| Andrew Dudum | Chief Executive Officer, Director | 16,686,948 |
| Soleil Boughton | Chief Legal Officer | 314,648 |
| Patrick Harrison Carroll | Chief Medical Officer | 213,574 |
| Michael Chi | Chief Operating Officer | 487,848 |
| Oluyemi Okupe | Chief Financial Officer | 277,559 |
| Mohamed Elshenawy | CTO | 278,044 |
| Jonathan M. Franklin | Chief Accounting Officer | – |
| Irene Becklund | PAO | 20,475 |
| Nader Kabbani | Chief Operating Officer | – |
| Melissa Baird | Chief Operating Officer | 817,829 |
| David B. Wells | Director | 230,859 |
| Christopher D. Payne | Director | 145,673 |
| Andrew D. Huberman | Director | – |
| Kare Schultz | Director | 26,020 |
| Kofi Owusu Amoo-Gottfried | Director | – |
| Anja Manuel | Director | 38,671 |
| Garcia Andrea G. Perez | Director | 83,822 |
| Delos M. Cosgrove | Director | 67,995 |
| Christiane Pendarvis | Director | 55,430 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $22.96M | $159.73M | $17.51M | $210 | $113 |
| FY2024 | $24.61M | $110.27M | $7.24M | $157 | $98 |
| FY2023 | $14.40M | $21.36M | $6.53M | $58 | $76 |
| FY2022 | $10.82M | $10.73M | $4.99M | $42 | $47 |
| FY2021 | $15.23M | $26.76M | $3.33M | $42 | $90 |
| FY2020 | $26.58M | $74.02M | $3.86M | $0 | $0 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Dudum Chief Executive Officer and Chairman | $494.79K | – | $10.64M | $11.00M | $585.76K | $243.00K | $22.96M | -7% |
| Okupe Chief Financial Officer | $530.88K | – | $7.47M | – | $376.76K | $17.48K | $8.40M | +2% |
| Elshenawy Chief Technology Officer | $375.00K | $3.00M | $57.22M | – | $278.47K | – | $60.87M | – |
| Chi Chief Operating Officer (previously Chief Commercial Officer) | $485.00K | – | $6.90M | – | $340.91K | $3.00K | $7.73M | +10% |
| Boughton Chief Legal Officer | $464.38K | – | $4.02M | – | $305.07K | $3.00K | $4.80M | +3% |
| Baird Former Chief Operating Officer | $341.29K | – | $8.05M | – | – | $3.00K | $8.39M | -8% |
| Kabbani Former Chief Operating Officer | $227.27K | $1.00M | $13.49M | – | – | $148.83K | $14.86M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Jul 19, 2019
- Offer price
- $10.00
- Securities offered
- 17,500,000
- Gross proceeds
- $175.00M
- Exchange
- NYSE
- First trading day
- Sep 9, 2019
- First-day close
- $9.88-1.2%
- Lock-up ends (est.)
- Mar 7, 2020
“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-third of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“Our number of employees has also increased significantly over the last few years, from 1,046 employees as of December 31, 2023 to 2,442 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 9, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Jan 26, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 26, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 21, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Jan 19, 2021 | Name change | Name changed from Oaktree Acquisition Corp. to Hims & Hers Health, Inc. |
| Oct 23, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jul 19, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 16, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?